神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/0100482798

このアイテムのアクセス数:79件（2024-05-24 07:08 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
0100482798 (fulltext) pdf 1.00 MB 45

メタデータ

ファイル出力

メタデータID
0100482798
アクセス権
open access
出版タイプ
Version of Record
タイトル
Rapid reduction of adenomyosis coexisting with leiomyoma volume during treatment with Relugolix
著者
Yamanaka, Keitaro ; Washio, Keiichi ; Uchida, Akiko ; Sasagawa, Yuki ; Nishimoto, Masashi ; Yamasaki, Yui ; Nagamata, Satoshi ; Terai, Yoshito
著者名
Yamanaka, Keitaro
著者ID
A3117
研究者ID
1000080940006
著者名
Washio, Keiichi
鷲尾, 佳一
ワシオ, ケイイチ
所属機関名
医学部附属病院
著者ID
A2537
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=8c042b380a6707f2520e17560c007669
著者名
Uchida, Akiko
内田, 明子
ウチダ, アキコ
所属機関名
医学部附属病院
著者ID
A2215
研究者ID
1000040815304
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=30c345fd94956baf520e17560c007669
著者名
Sasagawa, Yuki
笹川, 勇樹
ササガワ, ユウキ
所属機関名
医学研究科
著者ID
A3118
研究者ID
1000020943591
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=645e3d50a9b6ab62520e17560c007669
著者名
Nishimoto, Masashi
西本, 昌司
ニシモト, マサシ
所属機関名
医学部附属病院
著者ID
A2848
研究者ID
1000040895265
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=3e07e48170644619520e17560c007669
著者名
Yamasaki, Yui
山崎, 友維
ヤマサキ, ユイ
所属機関名
医学研究科
著者ID
A2160
研究者ID
1000050816642
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=50755f8c3d0b05df520e17560c007669
著者名
Nagamata, Satoshi
長又, 哲史
ナガマタ, サトシ
所属機関名
医学研究科
著者ID
A2519
研究者ID
1000090278531
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=e6b93f8aa70c4ebd520e17560c007669
著者名
Terai, Yoshito
寺井, 義人
テライ, ヨシト
所属機関名
医学部附属病院
収録物名
Gynecological Endocrinology
巻(号)
39(1)
ページ
2237121
出版者
Taylor & Francis
刊行日
2023-12-14
公開日
2023-08-18
抄録
Objective: This study elucidated the efficacy of Relugolix (REL) on the reduction of uterine volume and clinical symptoms for the treatment of adenomyosis. Methods: We conducted a retrospective cohort study of patients who received REL (40 mg for about 20 weeks) and who underwent a hysterectomy for adenomyosis or fibroids. We divided patients into two groups: adenomyosis coexisting with fibroids (Group A) and fibroids only (Group B); the groups were determined by a postoperative pathological examination. The primary end points were the percent reduction in uterine volume, adenomyotic lesion, and the largest fibroid volume at week 16. The secondary end points were the rate of amenorrhea, pelvic pain, and anemia at week 12. Results: A total of 56 patients participated in the current study: 20 in Group A and 36 in Group B. Regarding the largest fibroid volume, there was no significant difference between the two groups. Uterine volume after REL treatment was significantly decreased in Group A (43%), as compared to Group B (27%) (p = .00972), In Group A, adenomyotic lesion was decreased by 61%. Irrespective of the group, adenomyosis showed a significant reduction compared to uterine fibroids (p < .001). There was no statistically significant difference in the mitigation of symptoms (amenorrhea, pelvic pain, and anemia) between the two groups. Conclusions: REL is more effective in reducing adenomyotic lesion than uterine fibroids and in relieving symptoms (amenorrhea, pelvic pain, and anemia). It can be expected that REL will also be used as a preoperative treatment for adenomyosis.
キーワード
Adenomyosis
relugolix
fibroids
GnRH antagonist
GnRH agonist
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
CC license
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.